Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus

Human Molecular Genetics

Volumn 19, Issue 19, 2010, Pages 3852-3862

  Johanneson, Bo ^a   McDonnell, Shannon K ^b   Karyadi, Danielle M ^a   Quignon, Pascale ^a   McIntosh, Laura ^c   Riska, Shaun M ^b   FitzGerald, Liesel M ^c   Johnson, Gregory ^a   Deutsch, Kerry ^d   Williams, Gabrielle ^a   Tillmans, Lori S ^f   Stanford, Janet L ^c,e   Schaid, Daniel J ^b   Thibodeau, Stephen N ^f   Ostrander, Elaine A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c USA   (United States)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APOL3 GENE; ARTICLE; CANCER FAMILY; CANCER RISK; CASE CONTROL STUDY; CHROMOSOME 22Q; CONTROLLED STUDY; FAMILIAL CANCER; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; APOLIPOPROTEINS; CHROMOSOMES, HUMAN, PAIR 22; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; TATA BOX;

EID: 77956547385     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq283     Document Type: Article

References (46)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225.
2. Easton, D.F., Schaid, D.J., Whittemore, A.S. and Isaacs, W.J. (2003) Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate, 57, 261-269.
3. Ostrander, E.A. and Friedrichsen, D.M. (2004) Genetic factors: finding cancer susceptibility genes. In: Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B. and McKenna, W.G. (eds), Clinical Oncology, 3rd edn. Elsevier Science, Philadelphia, PA, pp. 253-267.
4. Schaid, D.J. (2004) The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet., 13 (Spec. 1), R103-R121.
5. Ostrander, E.A. and Johannesson, B. (2008) Prostate cancer susceptibility: finding the genes. Adv. Exp. Med. Biol., 617, 179-190.
6. Cunningham, J.M., McDonnell, S.K., Marks, A., Hebbring, S., Anderson, S.A., Peterson, B.J., Slager, S., French, A., Blute, M.L., Schaid, D.J. et al. (2003) Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate, 57, 335-346.
7. Janer, M., Fredrichsen, D., Stanford, J.L., Badzioch, M.D., Kolb, S., Deutsch, K., Peters, M.A., Goode, E.L., Welti, R., DeFrance, H.B. et al. (2003) A genomic scan of 254 hereditary prostate cancer families. Prostate, 57, 309-319.
8. Lange, E.M., Gillanders, E.M., Davis, C.C., Brown, W.M., Campbell, J.K., Jones, M., Gildea, D., Riedesel, E., Albertus, J., Freas-Lutz, D. et al. (2003) Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate, 57, 326-334.
9. Camp, N.J., Farnham, J.M. and Cannon Albright, L.A. (2005) Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate, 65, 365-374.
10. Chang, B.L., Isaacs, S.D., Wiley, K.E., Gillanders, E.M., Zheng, S.L., Meyers, D.A., Walsh, P.C., Trent, J.M., Xu, J. and Isaacs, W.B. (2005) Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate, 64, 356-361.
11. Stanford, J.L., McDonnell, S.K., Friedrichsen, D.M., Carlson, E.E., Kolb, S., Deutsch, K., Janer, M., Hood, L., Ostrander, E.A. and Schaid, D.J. (2006) Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate, 66, 317-325.
12. Xu, J., Dimitrov, L., Chang, B.L., Adams, T.S., Turner, A.R., Meyers, D.A., Eeles, R.A., Easton, D.F., Foulkes, W.D., Simard, J. et al. (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am. J. Hum. Genet., 77, 219-229.
13. Camp, N.J., Cannon-Albright, L.A., Farnham, J.M., Baffoe-Bonnie, A.B., George, A., Powell, I., Bailey-Wilson, J.E., Carpten, J.D., Giles, G.G., Hopper, J.L. et al. (2007) Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum. Mol. Genet., 16, 1271-1278.
14. Camp, N.J., Farnham, J.M. and Cannon-Albright, L.A. (2006) Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. Cancer Res., 66, 10205-10212.
15. Johanneson, B., McDonnell, S.K., Karyadi, D.M., Hebbring, S.J., Wang, L., Deutsch, K., McIntosh, L., Kwon, E.M., Suuriniemi, M., Stanford, J.L. et al. (2008) Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum. Genet., 123, 65-75.
16. Allen-Brady, K., Wong, J. and Camp, N. (2006) PedGenie: an analysis approach for genetic association testing in extended pedigrees and genealogies of arbitrary size. BMC Bioinformatics, 7, 209.
17. Li, M., Boehnke, M. and Abecasis, G.R. (2005) Joint modeling of linkage and association: identifying SNPs responsible for a linkage signal. Am. J. Hum. Genet., 76, 934-949.
18. Li, M., Boehnke, M. and Abecasis, G.R. (2006) Efficient study designs for test of genetic association using sibship data and unrelated cases and controls. Am. J. Hum. Genet, 78, 778-792.
19. Duchateau, P.N., Pullinger, C.R., Cho, M.H., Eng, C. and Kane, J.P. (2001) Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J. Lipid Res., 42, 620-630.
20. Stanford, J.L., Wicklund, K.G., McKnight,B., Daling, J.R. andBrawer, M.K. (1999) Vasectomy and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 8, 881-886.
21. Agalliu, I., Salinas, C.A., Hansten, P.D., Ostrander, E.A. and Stanford, J.L. (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am. J. Epid., 168, 250-260.
22. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello, M.J., Fearnhead, P., Yu, K., Chatterjee, N. et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet., 39, 645-649.
23. Bucher, P. (1990) Weight matrix descriptions of four eukaryotic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J Mol. Biol., 212, 563-578.
24. Ponjavic, J., Lenhard, B., Kai, C., Kawai, J., Carninci, P., Hayashizaki, Y. and Sandelin, A. (2006) Transcriptional and structural impact of TATA-initiation site spacing in mammalian core promoters %U. Genome Biol., 7, R78. http://genomebiology.com/2006/7/8/R78.
25. Vanhollebeke, B. and Payes, E. (2006) The function of apolipoproteins L. Cell. Mol. Life Sci., 63, 1937-1944.
26. Smith, E.E. and Malik, H.S. (2009) The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res, 19, 850-858.
27. Page, N.M., Butlin, D.J., Lomthaisong, K. and Lowry, P.J. (2001) The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics, 74, 71-78.
28. Liu, Z., Lu, H., Jiang, Z., Pastuszyn, A. and Hu, C.A. (2005) Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol. Cancer Res., 3, 21-31.
29. Vanhollebeke, B. and Pays, E. (2006) The function of apolipoproteins L. Cell. Mol. Life Sci., 63, 1937-1944.
30. Horrevoets, A.J., Fontijn, R.D., van Zonneveld, A.J., de Vries, C.J., ten Cate, J.W. and Pannekoek, H. (1999) Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood, 93, 3418-3431.
31. Matsuda, A., Suzuki, Y., Honda, G., Muramatsu, S., Matsuzaki, O., Nagano, Y., Doi, T., Shimotohno, K., Harada, T., Nishida, E. et al. (2003) Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene, 22, 3307-3318.
32. Eeles, R.A., Kote-Jarai, Z., Al Olama, A.A., Giles, G.G., Guy, M., Severi, G., Muir, K., Hopper, J.L., Henderson, B.E., Haiman, C.A. et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet., 41, 1116-1121.
33. Sun, J., Zheng, S.L., Wiklund, F., Isaacs, S.D., Li, G., Wiley, K.E., Kim, S.-T., Zhu, Y., Zhang, Z., Hsu, F.-C. et al. (2009) Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res., 69, 10-15.
34. Chute, C.G., Panser, L.A., Girman, C.J., Oesterling, J.E., Guess, H.A., Jacombsen, S.J. and Lieber, M.M. (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol, 150, 85-89.
35. Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren, W.L., Erdos, M.R., Stringham, H.M., Chines, P.S., Jackson, A.U. et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 316, 1341-1345.
36. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
37. IHC (2003) The International HapMap Project. Nature, 426, 789-796.
38. Rozen, S. and Skaletsky, H. (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol, 132, 365-386.
39. Ewing, B. and Green, P. (1998) Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res., 8, 186-194.
40. Ewing, B., Hillier, L., Wendl, M.C. and Green, P. (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res., 8, 175-185.
41. Gordon, D., Abajian, C. and Green, P. (1998) Consed: a graphical tool for sequence finishing. Genome Res, 8, 195-202.
42. Nickerson, D.A., Tobe, V.O. and Taylor, S.L. (1997) PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res., 25, 2745-2751.
43. Tobler, A.R., Short, S., Andersen, M.R. et al. (2005) The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J. Biomol. Tech., 16, 398-406.
44. De la Vega, F.M., Lazaruk, K.D., Rhodes, M.D. and Wenz, M.H. (2005) Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP genotyping assays and the SNPlex genotyping system. Mutat. Res., 573, 111-135.
45. Breslow, N.E. and Day, N.E. (1980) Statistical Methods in Cancer Research. Volume I. The Analysis of Case-control Studies. Lyon: IARC Scientific Publications.
46. Li, Y., Willer, C.J., Sanna, S. and Abecasis, G.R. (2009) Genotype imputation. Annu. Rev. Genomics Hum. Genet., 10, 387-406.